Elix & Tohoku University Team Up to Tackle Undruggable Proteins with AI-Driven Drug Discovery
Elix, a pioneering AI drug discovery company, has teamed up with Tohoku University to advance AI-driven drug development. The collaboration focuses on small-molecular PROTACs and targeted protein degradation (TPD), aiming to tackle traditionally 'undruggable' proteins.
Elix specialises in reducing drug development costs and enhancing success rates through AI and machine learning. Its platform, Elix DiscoveryTM, supports both ligand-based drug design (LBDD) and structure-based drug design (SBDD), enabling exploration across different approaches. The intuitive GUI allows users to construct predictive models and generate molecular structures.
The joint project with Tohoku University will develop compounds that act on critical targets for cellular homeostasis. This could potentially expand next-generation therapy possibilities. Minoru Ishikawa's research group, a pioneer in TPD research in Japan, will collaborate with Elix to accelerate ligand discovery for TPD and propose new therapeutic strategies for intractable diseases.
Elix and Tohoku University's collaboration seeks to harness AI technologies for drug discovery. By focusing on small-molecular PROTACs and TPD, they aim to target traditionally undruggable proteins, potentially opening new avenues for treating intractable diseases.
Read also:
- Is it advisable to utilize your personal health insurance in a publicly-funded medical facility?
- Dietary strategies for IBS elimination: Aims and execution methods
- Benefits, suitable dosage, and safety considerations for utilizing pumpkin seed oil in treating an overactive bladder
- Harmful Medical Remedies: A Misguided Approach to Healing
